Clinical Trials: Lung Cancer
Prevention Trials
Therapeutic Area: Non-Small Cell Lung Cancer
Principal Investigator: Dr. Susan Tannenbaum
Title: E5597: A phase III chemoprevention trial of selenium supplementation in persons with resected stage 1 Non-Small Cell Lung cancer
Description: The purpose of this study is to determine if selenium can reduce the incidence of second primary lung tumors in patients who have been surgically treated for
Stage I non-small cell lung cancer. Subjects will first take part in a 4 week trial to determine if they can remember to take medication on a daily basis. Following demonstration
that the subject can, the subject will be randomized to receive either selenium or placebo.
Length/Duration: Maximum of 4 years
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to dnoel@uchc.edu
IRB #: 01-178
Sponsor: Eastern Oncology Cooperative Group (ECOG)
 Treatment
Therapeutic Area: Non-Small Cell Lung Cancer
Principal Investigator: Dr. Susan Tannenbaum
Title: E3598: Phase III trial of carboplatin, paclitaxel and thoracic radiation therapy with or without thalidomide for stage III NSCLC
Description: The purpose of this study is to determine if the addition of thalidomide to chemotherapy and radiation therapy for stage IIIA or IIIB NSCLC will increase
survival.
Length/Duration: Treatment may be for up to 24 months, 5 years of follow-up.
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to dnoel@uchc.edu
IRB #: 00-181
Sponsor: Eastern Oncology Cooperative Group (ECOG)
|
Research
done today will be the standard treatments of tomorrow.